The ShinesRooms.com Provides Stock Research onValeant Pharmaceuticals International Inc. and pSivida Corp.
New York City, New York -- The drug delivery industry is seeing a major transformation. The focus of the industry now is to develop more user friendly devices as more and more patients administer drugs on their own. For companies such as Valeant Pharmaceuticals International Inc. (VRX) and pSivida Corp. (PSDV), the key will be to keep evolving as the industry continues to transform.
Access our free reports onValeant Pharmaceuticals International Inc. andpSivida Corp. Traders can also connect to our Wall Street Trading Floor where our research desk and market pros are standing between 8:50 am to 4:15 pm ET at
The drug delivery industry, over the years, has evolved. Companies these days are focusing on the development of needle-free injectors and other user friendly devices. The need for developing such devices has been driven by the fact that more and more patients are now administering drugs in home environment. Going forward, growth in the drug delivery industry will be driven by nanotechnology. Several drug companies are using nanotechnology to develop drug delivery products.
Investors are eyeing Valeant Pharmaceuticals International Inc.’s fourth quarter 2012 results, which are scheduled to be released on February 28, 2013. The Canada-based company has made some major acquisitions this month. Earlier this month, Valeant Pharmaceuticals announced that it completed the acquisition of Natur Produkt in Russia. Valeant acquired the Russian specialty pharmaceutical company for approximately $163 million. Natur Produkt focuses on the over-the-counter segment in several categories. Its key brands include AntiGrippin, Anti Angin, Sage and Eucaplyptus MA. Our free research report onValeant Pharmaceuticalscan be downloaded upon registration at
Valeant Pharmaceuticals also announced this month that it acquired U.S. rights for Targretin® capsules and Targretin® gel 1% from Eisai for $65 million upfront. The company will also make contingent payments if certain milestones are achieved.
For the third quarter of 2012, Valeant had reported total revenue of $884 million, with the company’s organic revenue growing 14%. GAAP earnings for the third quarter of 2012 were $0.02 per share.
J. Michael Pearson, Chairman and CEO of Valeant, said at the time of the release of third quarter results that the continued strength in the company’s base business, coupled with the potential approval of efinaconazole and the pending acquisition of Medicis should provide it with a solid foundation to deliver strong continued growth in 2013 and beyond.
Earlier this month, pSivida Corp. reported its financial results for the second quarter ended December 31, 2012. The company’s revenue for the quarter was $585,000, compared to $630,000 reported for the same period in the previous year. Net loss for the quarter was $2.6 million, or $0.11 per share, compared to net loss of $17.5 million, or $0.84 per share, reported for the same period in the previous year. pSivida Corp. free research is available today at
Dr. Paul Ashton, President and CEO of pSivida Corp., said earlier this month that the company is pleased with the progress of its lead development product, an injectable micro-insert for posterior uveitis. Ashton said that the company expects to begin Phase III trials early next quarter on schedule and intends these trials to form the basis for a future NDA submission.
Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.ShinesRooms.com is the Ultimate Trading Environment for investors. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing at
To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html
Michael Thomas Smith